Blood-based prognostic scores and early dynamics under immunotherapy to select patients with metastatic solid tumors for continuing immune check-point inhibition: a prospective longitudinal study
Cancer Immunology, Immunotherapy · 2025
DOI: 10.1007/s00262-024-03933-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Javier García-Corbacho und 22 weiteren Autor:innen. Beteiligte Einrichtung: The Clinical Trials Unit of Medical Oncology Department, Virgen de la Victoria University Hospital/IBIMA, Campus de Teatinos S/N, 29010, Malaga, Spai…. Hauptthemen laut MEDLINE: Neoplasms, Immune Checkpoint Inhibitors, Immunotherapy, Biomarkers, Tumor. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitat de Barcelona.
Abstract (Originalsprache)
Introduction
Immune check-point inhibitors (ICI) were a major breakthrough in cancer care, but optimal patient selection remains elusive in most tumors.
Methods
Overall 173 adult patients with metastatic solid tumors candidates to ICI in clinical trials at our Institution were prospectively recruited. Blood samples were collected at cycle 1 (C1D1) and 2 (C2D1) and until the occurrence of progressive disease (PD). C1D1 LIPI, RMH, PMHI, NLR, dNLR, PIPO and GRIm prognostic scores were calculated. The primary endpoint was identifying the best score to predict rapid PD (≤ 4 months) with ICI using logistic regressions accounting for tumor type, and receiving operators characteristics (ROC) with area under curve (AUC), accompanied by an extensive comparison of the score performances in the prediction of overall survival (OS), progression-free survival (PFS), overall response rates (ORR) and durable clinical benefit (DCB). Secondary objectives included describing study cohort outcomes and studying the association between the selected score at C1D1, C2D1 and its dynamics with OS and PFS.
Results
C1D1 LIPI was the best predictor of rapid PD, OS and PFS, regardless of cancer type, compared to other scores. No score was associated to ORR and only RMH to DCB. Baseline LIPI detected three categories of patients with significantly different OS ( p < 0.001) and PFS ( p = 0.013). The same was observed at C2D1 for OS and PFS (both p = 0.020). Significant LIPI class shifts were observed in the overall population ( p < 0.001), rapid progressors ( p = 0.029) and non-rapid progressors ( p = 0.009). Retaining a good LIPI or experiencing a shift towards a better prognostic class was associated to improved OS ( p = 0.009) and PFS ( p = 0.006). C2D1 LIPI, but not C1D1, remained significantly associated to rapid PD in multivariable analysis.
Conclusions
LIPI may improve patient selection for ICI and guide treatment adjustments according to on-treatment dynamics in a pancancer context.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Clinical Trials Unit of Medical Oncology Department, Virgen de la Victoria University Hospital/IBIMA, Campus de Teatinos S/N, 29010, Malaga, Spain. jgcorbacho@ibima.eu.
- Programa de Doctorado en Biomedicina, Universitat de Barcelona, Barcelona, Spain. jgcorbacho@ibima.eu.
- Medical Oncology Department, Hospital Clinic of Barcelona, C. Enric Granados, 86-88, 08008, Barcelona, Spain.
- Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
- Medical Oncology Department, Hospital General of Granollers, Granollers (BCN), Spain.
- Immunology Service, Hospital Clinic of Barcelona, Clinic Foundation for Biomedical Research - August Pi I Sunyer Biomedical Research Institute (FCRB-IDIBAPS), Barcelona, Spain.
Förderung
- Universitat de Barcelona
Zitieren
APA
García-Corbacho, J., Indacochea, A., Victoria, I., Moreno, D., Angelats, L., González Navarro, A. E., Mezquita, L., Brasó-Maristany, F., Galván, P., Mellado, B., Viñolas, N., Sauri, T., Nogué, M., Adamo, B., Maurel, J., Pineda, E., Gaba, L., Reig, O., Basté, N., …, & Schettini, F. (2025). Blood-based prognostic scores and early dynamics under immunotherapy to select patients with metastatic solid tumors for continuing immune check-point inhibition: a prospective longitudinal study. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-024-03933-w
Vancouver
García-Corbacho J, Indacochea A, Victoria I, Moreno D, Angelats L, González Navarro AE, et al. Blood-based prognostic scores and early dynamics under immunotherapy to select patients with metastatic solid tumors for continuing immune check-point inhibition: a prospective longitudinal study. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-024-03933-w
BibTeX
@article{GarcaCorbacho2025,
author = {García-Corbacho, Javier and Indacochea, Alberto and Victoria, Iván and Moreno, Débora and Angelats, Laura and González Navarro, Azucena E and Mezquita, Laura and Brasó-Maristany, Fara and Galván, Patricia and Mellado, Begoña and Viñolas, Nuria and Sauri, Tamara and Nogué, Miquel and Adamo, Barbara and Maurel, Joan and Pineda, Estela and Gaba, Lydia and Reig, Oscar and Basté, Neus and Sanfeliu, Esther and Juan, Manel and Prat, Aleix and Schettini, Francesco},
title = {Blood-based prognostic scores and early dynamics under immunotherapy to select patients with metastatic solid tumors for continuing immune check-point inhibition: a prospective longitudinal study},
journal = {Cancer Immunology, Immunotherapy},
year = {2025},
doi = {10.1007/s00262-024-03933-w}
}
EUVIMED